|
Wednesday, May 18, 2005
Androclus Therapeutics Gets Venture Funding
San Diego-based Androclus Therapeutics has raised a round of venture funding from E. de Rothschild Investment Partners and Matignon Technologies. The company is developing therapeutics targeting autoimmune and inflammatory diseases including rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. The company currently has a drug candidate, an orally administered immunomodulatory peptide for the treatment of RA, in Phase II clinical trials.
posted on Wednesday, May 18, 2005 (Link to more information)
|
 RSS
 Email
Twitter
Previous news:
Thursday, November 20, 2008
Wednesday, November 19, 2008
Tuesday, November 18, 2008
Monday, November 17, 2008
Friday, November 14, 2008
|
